{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T17:52:27Z","timestamp":1773251547804,"version":"3.50.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","dldjournalonline.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.dld.2024.01.199","type":"journal-article","created":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T17:17:27Z","timestamp":1707499047000},"page":"1582-1591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care"],"prefix":"10.1016","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2470-7230","authenticated-orcid":false,"given":"Benedetta","family":"Stefanini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Bucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Santi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Reggidori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-5829","authenticated-orcid":false,"given":"Lorenzo","family":"Lani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Granito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pelizzaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Cabibbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariella","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giorgia","family":"Ghittoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Campani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Svegliati-Baroni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8526-837X","authenticated-orcid":false,"given":"Edoardo G.","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Biasini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3053-4359","authenticated-orcid":false,"given":"Carlo","family":"Saitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donatella","family":"Magalotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Sangiovanni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0460-4122","authenticated-orcid":false,"given":"Maria","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Gasbarrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian Ludovico","family":"Rapaccini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Masotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Sacco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianpaolo","family":"Vidili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0458-3763","authenticated-orcid":false,"given":"Andrea","family":"Mega","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Azzaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8344-6523","authenticated-orcid":false,"given":"Gerardo","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Brandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2562-8526","authenticated-orcid":false,"given":"Simone","family":"Sabbioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6393-6995","authenticated-orcid":false,"given":"Franco","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.dld.2024.01.199_bib0001","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","article-title":"Global burden of primary liver cancer in 2020 and predictions to 2040","volume":"77","author":"Rumgay","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.01.199_bib0002","series-title":"StatPearls","article-title":"Use of the Child Pugh score in liver disease","author":"Tsoris","year":"2019"},{"issue":"5","key":"10.1016\/j.dld.2024.01.199_bib0003","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1016\/j.jhep.2021.11.013","article-title":"The importance of liver functional reserve in the non-surgical treatment of hepatocellular carcinoma","volume":"76","author":"D'Avola","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.01.199_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221086126","article-title":"Frontline therapy for advanced hepatocellular carcinoma: an update","volume":"15","author":"Akce","year":"2022","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.dld.2024.01.199_bib0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1200\/JCO.2022.40.4_suppl.379","article-title":"Phase 3 randomized, open-label, multicenter study of tremelimumab and durvalumab as first-line therapy in patients with unresectable hepatocellular carcinoma: HIMALAYA","volume":"40","author":"Abou-Alfa","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.dld.2024.01.199_bib0006","article-title":"Predictive and prognostic potential of liver function assessment in patients with advanced hepatocellular carcinoma: a systematic literature review","volume":"1","author":"Vogel","year":"2023","journal-title":"Liver Cancer"},{"issue":"6","key":"10.1016\/j.dld.2024.01.199_bib0007","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","article-title":"Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study","volume":"65","author":"Marrero","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.01.199_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma-a meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.dld.2024.01.199_bib0009","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1634\/theoncologist.2013-0093","article-title":"Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study","volume":"18","author":"Brandi","year":"2013","journal-title":"The Oncologist"},{"issue":"6","key":"10.1016\/j.dld.2024.01.199_bib0010","first-page":"518","article-title":"Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure","volume":"47","author":"Granito","year":"2015","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"10.1016\/j.dld.2024.01.199_bib0011","doi-asserted-by":"crossref","first-page":"42499","DOI":"10.1038\/srep42499","article-title":"Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study","volume":"7","author":"Casadei Gardini","year":"2017","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.dld.2024.01.199_bib0012","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s00432-017-2556-6","article-title":"Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation","volume":"144","author":"Trevisani","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"10.1016\/j.dld.2024.01.199_bib0013","doi-asserted-by":"crossref","first-page":"9997","DOI":"10.1038\/s41598-018-28337-6","article-title":"Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: a proof of concept","volume":"8","author":"De Lorenzo","year":"2018","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.dld.2024.01.199_bib0014","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.dld.2024.01.199_bib0015","first-page":"61","article-title":"BOOST: a phase 3 trial of sorafenib vs. best supportive care in first line treatment of hepatocellular carcinoma in patients with deteriorated liver function","volume":"7","author":"Daniele","year":"2021","journal-title":"Hepatoma Res"},{"issue":"1","key":"10.1016\/j.dld.2024.01.199_bib0016","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s12072-020-10120-3","article-title":"PRODIGE 21 collaborators. Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis","volume":"15","author":"Blanc","year":"2021","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.dld.2024.01.199_bib0017","article-title":"Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)","volume":"45","author":"Kokudo","year":"2015","journal-title":"Hepatol Res Off J Jpn Soc Hepatol"},{"key":"10.1016\/j.dld.2024.01.199_bib0018","unstructured":"Linee Guida inter-societarie Epatocarcinoma 2023. https:\/\/www.iss.it\/documents\/20126\/8404074\/LG97_AISF-AIOM_Epatocarcinoma.pdf\/b33f32d9-79ad-8501-926e-ed689180ffd5?t=1678806522071."},{"issue":"1","key":"10.1016\/j.dld.2024.01.199_bib0019","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.dld.2024.01.199_bib0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.01.199_bib0021","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.annonc.2023.04.043","article-title":"Atezolizumab plus bevacizumab is associated with improved survival outcomes in HCC patients with Child-Pugh B dysfunction compared to best supportive therapy","volume":"34","author":"Fulgenzi","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.dld.2024.01.199_bib0022","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00535-019-01642-1","article-title":"REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset","volume":"55","author":"Yamashita","year":"2020","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.dld.2024.01.199_bib0023","unstructured":"Pasta A., Calabrese F., Jaffe A., et al. Safety and efficacy of atezolizumab\/bevacizumab in patients with hepatocellular carcinoma and impaired liver function: a systematic review and meta-analysis. Liver Cancer, in press."},{"issue":"3","key":"10.1016\/j.dld.2024.01.199_bib0024","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s12032-013-0655-z","article-title":"Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma","volume":"30","author":"Abdel-Rahman","year":"2013","journal-title":"Med Oncol"},{"issue":"7","key":"10.1016\/j.dld.2024.01.199_bib0025","doi-asserted-by":"crossref","first-page":"e312","DOI":"10.1016\/S1470-2045(23)00186-9","article-title":"Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept","volume":"24","author":"Vitale","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.dld.2024.01.199_bib0026","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.dld.2024.01.199_bib0027","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.dld.2022.07.003","article-title":"Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors","volume":"54","author":"Stefanini","year":"2022","journal-title":"Dig Liver Dis"},{"issue":"4","key":"10.1016\/j.dld.2024.01.199_bib0028","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1097\/HEP.0000000000000030","article-title":"Outcome of patients with HCC and liver dysfunction under immunotherapy: a systematic review and meta-analysis","volume":"77","author":"El Hajra","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.dld.2024.01.199_bib0029","doi-asserted-by":"crossref","first-page":"4616","DOI":"10.3390\/cancers14194616","article-title":"Mechanisms of Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Patients with Hepatocellular Carcinoma","volume":"14","author":"De Lorenzo","year":"2022","journal-title":"Cancers"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824002421?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865824002421?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:59:07Z","timestamp":1725411547000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865824002421"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1590865824002421"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2024.01.199","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sorafenib and Metronomic Capecitabine in Child-Pugh B patients with advanced HCC: A real-life comparison with best supportive care","name":"articletitle","label":"Article Title"},{"value":"Digestive and Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dld.2024.01.199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}